

Supplementary Materials

Dysregulated STAT3 signaling and T cell immunometabolic dysfunction define a targetable, high mortality subphenotype of critically ill children

Authors: Robert B. Lindell^{1,2*}, Samir Sayed³, Jose S. Campos³, Montana Knight⁴, Andrea A. Mauracher³, Ceire A. Hay³, Peyton E. Conrey³, Julie C. Fitzgerald¹, Nadir Yehya¹, Stephen T. Famularo III¹, Teresa Arroyo¹, Richard Tustin III³, Hossein Fazelinia⁴, Edward M. Behrens⁵, David T. Teachey⁶, Alexandra F. Freeman⁷, Jenna R. E. Bergerson⁷, Steven M. Holland⁷, Jennifer W. Leiding⁸, Scott L. Weiss⁹, Mark W. Hall¹⁰, Athena F. Zuppa¹¹, Deanne M. Taylor⁴, Rui Feng¹², E. John Wherry^{2,13}, Nuala J. Meyer^{2,14}, Sarah E. Henrickson^{2,3}

* Corresponding author: Robert B. Lindell, LindellR@chop.edu

This PDF file includes:

- Supplemental methods
- Fig. S1. Supporting evidence for $k=3$ clusters in Fig. 2A.
- Fig. S2. PCA resolving three MODS subphenotypes based on expression of 24 elastic net derived severity-associated proteins.
- Fig. S3. Representative gating strategy for spectral flow immune phenotyping panel.
- Fig. S4. Results from single cell transcriptomics quality control and integration steps.
- Table S1. 1472 proteins measured in proteomics panel used in MODS and healthy control cohorts.
- Table S2. Antibodies used in 35-marker spectral flow immune phenotyping panel.
- Table S3. PCA loadings in Fig. 1D, using the full proteomics dataset.
- Table S4. Severity-associated proteins identified through linear mixed-effects model after adjustment for age, sex, and day from MODS onset.
- Table S5. Etiology of MODS and computed subphenotype for each patient with MODS.
- Table S6. Immunocompromised diagnoses by MODS subphenotype.
- Table S7. 368 proteins measured in proteomics panel used in IEI cohort.
- Table S8. Leading edge analysis of protein expression in Group C patients compared to HC participants.
- Table S9. Modified Proulx criteria used for screening and enrollment in the MODS cohort.
- Table S10. Age range and sex for each healthy control participant.
- Table S11. Final set of 1448 proteins which met quality control thresholds in all three experiments and were included in downstream analyses.
- Table S12. Gene sets used in GSEA and GSVA analysis.

SUPPLEMENTAL METHODS

PROTOCOL FOR THAWING AND STAINING HUMAN PBMCs FOR IMMUNE PROFILING ANALYSIS

PBMC Thawing Protocol

1. Prepare 15mL conical tubes with 10mL cRPMI (warmed 37°C water bath).
2. Obtain cryovials from LN and keep on dry ice until immediately before thaw.
3. Swirl 2 vials in 37°C water bath for ~30 seconds. Partially thawed pellet should remain.
4. Add 1mL warm cRPMI to cryovial and mix. Transfer all contents into 15mL tube.
5. Wash cryovial with 2mL warm cRPMI and transfer contents to 15mL tube.
6. Spin @ 800xg for 4 mins at RT.
7. Decant supernatant into waste and tap vial ridge to remove excess media.
8. Resuspend cells in 1mL warm cRPMI.
9. Count cells: 10µL Trypan blue + 10µL Cell suspension.
10. Spin @ 800xg for 4 mins at RT.
11. Decant supernatant into waste and tap vial ridge to remove excess media.
12. Resuspend cells in warm cRPMI at a concentration of 5×10^6 cells/mL.
13. Plate 200µL/well, or 1×10^6 cells/well, in a 96-well round bottom plate.

PBMC Staining Protocol

1. Spin at 800xg for 4 mins, RT. Flick plate to discard supernatant.
2. Wash cells with 150µL of PBS.
3. Spin at 800xg for 4 mins, RT. Flick plate to discard supernatant.
4. Resuspend cells in 50µL **LD/Fc stain mixture**.
5. Incubate at 4°C for 15 minutes.
6. Wash cells with 150µL of PBS.
7. Spin at 800xg for 4 mins, RT. Flick plate to discard supernatant.
8. Resuspend cells in 50µL **SS antibody mixture** in FACS Buffer + Brilliant Stain Buffer.
9. Incubate at 4°C for 30 minutes in the dark.
10. Wash with 150µL FACS buffer.
11. Spin @ 800xg for 4 mins, RT. Flick plate to discard supernatant.
12. Resuspend cells in 50µL of **Fix/Perm reagent**.
13. Incubate at RT for 20 minutes in the dark.
14. Wash with 150µL Perm buffer.
15. Spin @ 800xg for 4 mins, RT. Flick plate to discard supernatant.
16. Resuspend cells in 50µL **ICS antibody mixture** in Perm Buffer + Brilliant Stain Buffer.
17. Incubate at 4°C for 60 minutes in the dark.
18. Wash with 150µL of Perm Buffer.
19. Spin @ 800xg for 4 mins, RT. Flick plate to discard supernatant.
20. Resuspend pellets in 100µL **1.6% PFA fixative** and transfer to bullet tubes.
21. Cells can be held at 4°C overnight prior to acquisition.

PROTOCOL FOR THAWING AND STAINING HUMAN PBMCs FOR AURORA CS SORTING

PBMC Thawing Protocol

1. Prepare 15mL conical tubes with 10mL cRPMI (warmed 37°C water bath).
2. Obtain PBMC cryovials from LN and keep on dry ice until immediately before thaw.
3. Swirl 2 vials in 37°C water bath for ~30 seconds. Partially thawed pellet should remain.
4. Add 1mL warm cRPMI to cryovial and mix. Transfer all contents into 15mL tube.
5. Wash cryovial with 2mL warm cRPMI and transfer contents to 15mL tube.
6. Spin @ 800xg for 4 mins at RT.
7. Decant supernatant into waste and tap vial ridge to remove excess media.
8. Resuspend cells in 1mL warm cRPMI.
9. Count cells with 10µL trypan blue + 10µL cell suspension.
10. Lift 1×10^6 live cells into a new labeled tube for staining.

PBMC Staining Protocol

1. Spin at 800xg for 4 mins, RT. Decant/tap to remove excess media.
2. Wash cells with 1mL of FACS buffer.
3. Spin at 800xg for 4 mins, RT. Decant/tap to remove excess media.
4. Resuspend cells in 100µL **Stain Mixture**.
5. Incubate at RT for 30 minutes in the dark.
6. Wash cells with 1mL of FACS buffer.
7. Spin at 800xg for 4 mins, RT. Decant/tap to remove excess media.
8. Resuspend cells in 500µL FACS Buffer and pass through blue cell strainer into FACS tube.
9. Cover and keep on wet ice. Cells are ready for sorting.

Prepare Sort Tubes and Resuspension Media


1. Prepare three 1.5ml eppendorf tubes with 500µL of PBS + 20% FBS for each sample.
2. Prepare 10% FBS Resuspension Media.

Cell Washing and Resuspension


1. After sorting, spin down cells in microcentrifuge 800xg for 5 mins, 4 degrees.
2. Aspirate supernatant and wash with 500µL PBS + 10% FBS.
3. Spin down cells in microcentrifuge 800xg for 5 mins, 4 degrees.
4. Aspirate supernatant and wash with 500µL PBS + 10% FBS.
5. Spin down cells in microcentrifuge 800xg for 5 mins, 4 degrees.
6. Goal concentration is 1200 cells per microliter. Calculate resuspension volume.
7. Aspirate supernatant and resuspend in PBS + 10% FBS.
8. Cover and keep on wet ice. Cells are ready for 10x processing.

Fig. S1. Supporting evidence for $k=3$ clusters in Fig. 2A.

(A) This cumulative distribution function (CDF) plot demonstrates increased cluster stability up to $k=3$ (as indicated by flatter line), with decreasing cluster stability with finer clustering.



(B) Relative Cluster Stability Index (RCSI) is highest at $k=3$.



(C) M3C calculates empirical p -values from reference distributions to test the null hypothesis that $k=1$. In our analysis, at $k=3$ the null hypothesis is rejected ($p=0.038$).





Fig. S2. PCA resolving three MODS subphenotypes based on expression of 24 elastic net derived severity-associated proteins.



PCA dimensionality reduction demonstrates effective resolution of three MODS subphenotypes based on expression of 24 elastic net derived severity-associated proteins, with the majority of variance within the dataset defined by Dimension 1 as expected.

Fig. S3. Representative gating strategy for spectral flow immune phenotyping panel.






Fig. S4. Results from single cell transcriptomics quality control and integration steps.

(A) Quality Control


Cells with 1200-20000 transcripts per cell were retained for further analysis.




Cells with 750-500 unique genes per cell were retained for further analysis.



Cells with <20% mitochondrial DNA were retained for further analysis.




After applying these quality control steps, sample quality was consistent across groups.



(B) RPCA Integration

Unintegrated data demonstrates differences between Group C Patients and HC Participants.



Integration with RPCA resolves discrepancies between Group C Patients and HC Participants.




Table S1. 1472 proteins measured in proteomics panel used in MODS and healthy control cohorts.

Due to its size, Table S1 is available in the attached supplemental spreadsheet.

Table S2. Antibodies used in 35-marker spectral flow immune phenotyping panel.

MARKER	FLUOROPHORE	VENDOR	CLONE	CATALOG NO.
CD45RA	BUV395	BD Biosciences	H100	740298
Live/Dead	LD Blue	Thermo Fisher	N/A	L34961
CD16	BUV496	BD Biosciences	3G8	612944
CD26	BUV563	BD Biosciences	L272	749181
CD39	BUV661	BD Biosciences	TU66	749967
CD56	BUV737	BD Biosciences	NCAM16.2	612767
CD8	BUV805	BD Biosciences	SK1	612889
CCR7	BV421	BioLegend	G043H7	353208
CD123	Super Bright 436	Thermo Fisher	6H6	62-1239-42
CD161	eFluor 450	Thermo Fisher	HP-3G10	48-1619-41
ICOS	BV480	BD Biosciences	DX29	746248
Ki67	BV510	BD Biosciences	B56	563462
CD3	BV570	BioLegend	UCHT1	300436
CCR4	BV605	BioLegend	L291H4	359418
CD95	BV650	BioLegend	DX2	305642
CCR6	BV711	BioLegend	G034E3	353436
CXCR5	BV750	BD Biosciences	RF8B2	747111
PD-1	BV785	BioLegend	EH12.2H7	329930
Foxp3	Alexa Fluor 488	BioLegend	259D	320212
CD14	Spark Blue 550	BioLegend	63D3	367148
CD20	PerCP	BioLegend	2H7	302324
CD11b	PerCP-Cy5.5	BioLegend	ICRF44	301328
TCRγδ	PerCP-eFluor 710	Thermo Fisher	B1.1	46-9959-42
IgD	PE	BioLegend	IA6-2	348204
CD4	cFluor YG584	CYTEK	SK3	R7-20041-100T
Tbet	PE-Cy5	Thermo Fisher	4B10	15-5825-80
CD25	PE-Alexa Fluor 700	Thermo Fisher	CD25-3G10	MHCD2524
CXCR3	PE-Cy7	BioLegend	G025H7	353720
HLA-DR	PE-Fire 810	BioLegend	L243	307683
CRTH2	APC	BioLegend	BM16	350110
CD11c	Alexa Fluor 647	BioLegend	3.9	301620
CD19	Spark NIR 685	BioLegend	HIB19	302270
CD127	APC-R700	BD Biosciences	HIL-7R-M21	565185
CD27	APC-eFluor780	Thermo Fisher	O323	47-0279-42
CD38	APC/Fire 810	BioLegend	HIT2	303550

Table S3. PCA loadings in Fig. 1D, using the full proteomics dataset.

DIMENSION 1 (TOP 25 PROTEINS)	
PROTEIN NAME	CONTRIBUTION
POLR2F	0.92969158
MAD1L1	0.91356503
TXLNA	0.89474736
ELOA	0.86811405
DPY30	0.86400025
EGLN1	0.85809847
ZBTB17	0.85543741
APBB1IP	0.85335406
PXN	0.85301337
GPKOW	0.85281899
DFFA	0.85090827
OGFR	0.84328415
HDGF	0.841057
PLAUR	0.84001585
NUDC	0.83925242
INPP1	0.83863173
GFER	0.83484888
CKAP4	0.8330877
RAD23B	0.82862877
SRP14	0.82675401
NMMAT1	0.82477831
NBN	0.82470521
EZR	0.82439488
DCTPP1	0.82416125
HEXIM1	0.82383476

DIMENSION 2 (TOP 25 PROTEINS)	
PROTEIN NAME	CONTRIBUTION
ARHGEF12	0.92927293
DBNL	0.91717031
CASP3	0.91624786
PPP1R12A	0.90434238
SRC	0.90335717
CRKL	0.90060822
NT5C3A	0.89589151
PLXNA4	0.89309739
MAP2K6	0.88974514
CA13	0.88624933
TBC1D23	0.88578306
CLIP2	0.88413467
TJAP1	0.88285037
SKAP2	0.87773049
AXIN1	0.87715071
PDLIM7	0.87685547
MANF	0.87614294
CIAPIN1	0.87457034
MYO9B	0.87420508
SNAP29	0.87219403
MAP3K5	0.87165308
DNAJA2	0.86881494
CORO1A	0.86234331
CRACR2A	0.86216539
SNAP23	0.85969907

Table S4. Severity-associated proteins identified through linear mixed-effects model after adjustment for age, sex, and day from MODS onset.

Due to its size, Table S4 is available in the attached supplemental spreadsheet.

Table S5. Etiology of MODS and computed subphenotype for each MODS patient.

HASHED PATIENT ID	MODS ETIOLOGY	CAUSE OF SEPSIS	MODS SUBPHENOTYPE
1018	Cardiopulmonary Bypass	n/a	B
1168	Sepsis	Culture Negative Sepsis	B
1234	Sepsis	Culture Negative Sepsis	C
1344	Cardiopulmonary Bypass	n/a	B
1426	Sepsis	Culture Negative Sepsis	B
1501	Non-infected	n/a	B
1521	Sepsis	Bacterial Sepsis	B
1523	Non-infected	n/a	B
1568	Non-infected	n/a	B
1620	Non-infected	n/a	B
1670	Sepsis	Culture Negative Sepsis	B
1677	Non-infected	n/a	C
1845	Sepsis	Viral Sepsis	A
1947	Non-infected	n/a	B
1973	Non-infected	n/a	A
2040	Non-infected	n/a	C
2056	Cardiopulmonary Bypass	n/a	B
2166	Non-infected	n/a	A
2243	Cardiopulmonary Bypass	n/a	B
2274	Non-infected	n/a	C
2309	Cardiopulmonary Bypass	n/a	B
2314	Non-infected	n/a	C
2393	Sepsis	Culture Negative Sepsis	B
2439	Cardiopulmonary Bypass	n/a	B
2726	Non-infected	n/a	C
2997	Non-infected	n/a	A
3005	Sepsis	Bacterial Sepsis	C
3134	Sepsis	Bacterial Sepsis	C
3227	Sepsis	Viral Sepsis	C
3365	Sepsis	Culture Negative Sepsis	C
3502	Cardiopulmonary Bypass	n/a	B
3596	Non-infected	n/a	B
3638	Sepsis	Bacterial Sepsis	B
3645	Non-infected	n/a	B
3783	Non-infected	n/a	C
3986	Sepsis	Culture Negative Sepsis	B
4130	Sepsis	Viral Sepsis	B
4241	Sepsis	Culture Negative Sepsis	C
4464	Non-infected	n/a	B
4638	Non-infected	n/a	B
4798	Sepsis	Viral Sepsis	B
4807	Sepsis	Culture Negative Sepsis	B
4868	Sepsis	Viral Sepsis	B
4901	Sepsis	Culture Negative Sepsis	C
5017	Non-infected	n/a	A
5368	Sepsis	Culture Negative Sepsis	A
5401	Non-infected	n/a	C
5522	Sepsis	Culture Negative Sepsis	B
5565	Sepsis	Bacterial Sepsis	B
5700	Sepsis	Viral Sepsis	B
5734	Sepsis	Viral Sepsis	A
5791	Non-infected	n/a	C
5842	Sepsis	Culture Negative Sepsis	A
5859	Cardiopulmonary Bypass	n/a	C
5909	Non-infected	n/a	C
5931	Sepsis	Viral Sepsis	C
6126	Sepsis	Bacterial Sepsis	C
6134	Non-infected	n/a	A
6468	Sepsis	Culture Negative Sepsis	C
6499	Sepsis	Bacterial Sepsis	C
6564	Non-infected	n/a	A

HASHED PATIENT ID	MODS ETIOLOGY	CAUSE OF SEPSIS	MODS SUBPHENOTYPE
6606	Sepsis	Viral Sepsis	B
6698	Non-infected	n/a	B
7184	Non-infected	n/a	A
7331	Sepsis	Culture Negative Sepsis	C
7343	Non-infected	n/a	C
7411	Non-infected	n/a	C
7433	Non-infected	n/a	B
7632	Non-infected	n/a	B
7639	Non-infected	n/a	B
7791	Trauma	n/a	A
7810	Non-infected	n/a	A
7919	Non-infected	n/a	A
7977	Trauma	n/a	A
8047	Non-infected	n/a	B
8823	Non-infected	n/a	C
8825	Sepsis	Bacterial Sepsis	B
8877	Non-infected	n/a	C
8893	Trauma	n/a	A
9129	Trauma	n/a	A
9222	Non-infected	n/a	A
9328	Non-infected	n/a	B
9345	Non-infected	n/a	A
9480	Sepsis	Culture Negative Sepsis	C
9484	Non-infected	n/a	B
9630	Sepsis	Culture Negative Sepsis	C
9712	Sepsis	Viral Sepsis	C
9948	Non-infected	n/a	C

Table S6. Immunocompromised diagnoses by MODS subphenotype.

HASHED PATIENT ID	IMMUNOCOMPROMISED DIAGNOSIS	COMPUTED MODS SUBPHENOTYPE	SURVIVAL TO PICU DISCHARGE
5368	Cancer, solid tumor	A	Yes
6564	Cancer, leukemia	A	Yes
1521	Very early onset inflammatory bowel disease	B	Yes
3596	Hematopoietic cell transplant	B	Yes
5522	Cancer, solid tumor	B	No
5565	Cancer, solid tumor	B	Yes
7433	Cancer, solid tumor	B	No
9484	Cancer, leukemia	B	Yes
3227	Hematopoietic cell transplant	C	Yes
6499	Common variable immunodeficiency	C	No
9630	Cancer, solid tumor	C	Yes

Table S7. 368 proteins measured in proteomics panel used in IEI cohort.

Due to its size, Table S7 is available in the attached supplemental spreadsheet.

Table S8. Leading edge analysis of protein expression in Group C patients compared to HC participants.

HALLMARK PATHWAY	FDR ADJUSTED P-VALUE	LEADING EDGE ENRICHMENT
HALLMARK_IL6_JAK_STAT3_SIGNALING	0.004779285	IL6, CCL7, PLA2G2A, REG1A, JUN, HMOX1, IL4R, TNFRSF12A, TNFRSF1A, TNFRSF1B, CXCL10, CXCL9, IL2RA, IL15RA, IL18R1, LTBR, CSF1, CD38, CXCL11, ACVRL1, IL1B, CD14, TNF, CXCL13, IL12RB1, TGFB1, CSF2RA, FAS, IFNGR1
HALLMARK_XENOBIOTIC_METABOLISM	0.005617107	PTS, FABP1, IGFBP1, FBP1, REG1A, HMOX1, TNFRSF1A, NINJ1, AHCY, CES1, ARG1, DDC, IGFBP4, EPHA2, GSTA3, DCXR
HALLMARK_INFLAMMATORY_RESPONSE	0.008012074	IL6, CCL7, CXCL8, CSF3, CCL20, LIF, TIMP1, IL10, BST2, IL4R, OSM, TNFRSF1B, CXCL10, NAMPT, CXCL9, CCL2, IL15, PLAUR, CLEC5A, LDLR, IL15RA, PVR, IL18R1, ADM, LAMP3, CSF1, MSR1, LYN, CXCL11, IL1B, CX3CL1, SLAMF1, CD14
HALLMARK_INTERFERON_ALPHA_RESPONSE	0.016318021	BST2, IL4R, GBP2, CXCL10, IL15, CASP1, LAMP3, CSF1, CD74, OGFR, PSME2, LAP3, CXCL11
HALLMARK_TNFA_SIGNALING_VIA_NFKB	0.030735353	IL6, AREG, CCL20, LIF, SERPINB8, JUN, CXCL10, NAMPT, FOSB, NINJ1, CCL2, PLAUR, CEBPB, LDLR, IL15RA, TNC, SOD2, CSF1, CCN1, B4GALT1, PTX3, CXCL11, KYNU, IL1B, CCL4, TNF, NFKBIE, VEGFA, TANK, F3, IL18, ICAM1
HALLMARK_INTERFERON_GAMMA_RESPONSE	0.031250000	IL6, CCL7, BST2, IL4R, CXCL10, NAMPT, CXCL9, CCL2, IL15, CASP1, IL15RA, CD274, SOD2, IL18BP, CD38, CD74, OGFR, PSME2, VAMP5, LAP3, CXCL11
HALLMARK_OXIDATIVE_PHOSPHORYLATION	0.035126235	NDUFS6, GRPEL1, ACAA1, POLR2F, BAX, COX5B
HALLMARK_UNFOLDED_PROTEIN_RESPONSE	0.035144814	IGFBP1, ZBTB17, EIF4EBP1, CCL2, CEBPB, NPM1, FUS, PREB, BAG3, VEGFA
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	0.038038038	IL6, AREG, CXCL8, SDC1, PRSS2, TIMP1, JUN, FSTL3, TNFRSF12A, TFPI2, SFRP1, TNFRSF11B, THBS2, MMP3, IL15, ACTA2, TGM2, PLAUR, COL4A1, TNC, BGN, PVR, CAPG, IGFBP4, VCAN, IGFBP2
HALLMARK_ESTROGEN_RESPONSE_LATE	0.044102564	AREG, KRT19, AGR2, TFPI2, SORD, FKBP4, MDK, TFF1, IGFBP4, CA12, DCXR, SLC16A1, TFF3, BLVRB, MAPT, FABP5, FKBP5

Table S9. Modified Proulx criteria used for screening and enrollment in the MODS cohort.

ORGAN SYSTEM	CLINICAL AND LABORATORY CRITERIA FOR ORGAN DYSFUNCTION ¹
Respiratory Dysfunction	i) Respiratory rate > 90 breaths per min (age < 1yr) or > 70 breaths per min (age \geq 1yr) OR ii) PaO ₂ < 40 mmHg (5.3kPa) in absence of cyanotic congenital heart disease OR iii) PaCO ₂ \geq 65 mmHg (8.7kPa) OR iv) PaO ₂ /FiO ₂ < 200 in absence of cyanotic congenital heart disease (where P/F ratio is based on simultaneous measurements) OR v) Mechanical ventilation (1) Must be for > 24hrs post-operative if intubated just for surgery/procedure (2) Includes new HFNC \geq 6L/min, non-invasive ventilation (e.g. CPAP, BiPAP), and VV ECMO (3) Includes patients with tracheostomy who do NOT require mechanical ventilation at baseline (4) For subjects with non-invasive ventilation at baseline, intubation would qualify as Respiratory Dysfunction
Cardiovascular Dysfunction	i) Systolic blood pressure < 40 mmHg (age < 1yr) or < 50 mmHg (age \geq 1yr) OR ii) Heart rate < 50 or > 220 (age < 1yr), < 40 or > 200 (age \geq 1yr) OR iii) Cardiac arrest OR iv) pH < 7.2 with normal PaCO ₂ OR v) Continuous vasoactive drug infusion for hemodynamic support (excluding dopamine infusion \leq 5ug/kg/min) OR vi) VA ECMO OR vii) Ventricular assist device
Hematologic Dysfunction	i) Hemoglobin < 5g/dL (50g/L) OR ii) White blood cell count < 3,000/mm ³ (3×10^9 /L) OR iii) Platelet count < 20,000/mm ³ (20×10^9) OR iv) PT > 20 seconds OR aPTT > 60 seconds (in absence of anticoagulation therapy)
Gastrointestinal Dysfunction	i) Gastrointestinal bleeding AND one of the following believed to be the result of gastroduodenal bleeding: (1) Drop in hemoglobin \geq 2g/dL (20g/L) over 24 hours OR (2) Blood transfusion OR (3) Hypotension with blood pressure < 5th percentile of age OR (4) Gastric or duodenal surgery
Renal Dysfunction	i) Serum BUN \geq 100mg/dL (36 mmol/L) OR ii) Serum creatinine \geq 2 mg/dL (177 umol/L) without pre-existing renal disease OR iii) Dialysis and/or hemofiltration
Neurological Dysfunction	i) Fixed, dilated pupils OR ii) Glasgow coma score (GCS) < 5 in the absence of neuromuscular blocking drugs
Hepatic Dysfunction	i) Total bilirubin > 3mg/dL (60 umol/L)

- ¹ MODS criteria derived from: F. Proulx *et al.*, The pediatric multiple organ dysfunction syndrome. *Pediatr Crit Care Med* **10**, 12-22 (2009).

Table S10. Age range and sex for each healthy control participant.

HASHED PARTICIPANT ID	AGE RANGE (YEARS)	SEX
HC-105	6-10	M
HC-175	11-15	M
HC-182	0-5	F
HC-304	6-10	M
HC-335	11-15	M
HC-411	11-15	M
HC-417	16-20	M
HC-439	11-15	M
HC-500	6-10	M
HC-534	11-15	F
HC-549	0-5	F
HC-581	11-15	F
HC-598	11-15	F
HC-665	16-20	M
HC-679	6-10	F
HC-698	6-10	F
HC-730	6-10	M
HC-746	6-10	F
HC-778	6-10	M
HC-782	0-5	F
HC-841	0-5	F
HC-919	16-20	M
HC-937	0-5	M
HC-963	11-15	F
HC-979	6-10	M

Table S11. Final set of 1448 proteins which met quality control thresholds in all three experiments and were included in downstream analyses.

Due to its size, Table S11 is available in the attached supplemental spreadsheet.

Table S12. Gene sets used in GSEA and GSVA analysis.

GENE SET	GENE SYMBOLS
HALLMARK_TNFA_SIGNALING_VIA_NFKB	ABC1, ACKR3, AREG, ATF3, ATP2B1, B4GALT1, B4GALT5, BCL2A1, BCL3, BCL6, BHLHE40, BIRC2, BIRC3, BMP2, BTG1, BTG2, BTG3, CCL2, CCL20, CCL4, CCL5, CCN1, CCND1, CCNL1, CCRL2, CD44, CD69, CD80, CD83, CDKN1A, CEBPB, CEBPD, CFLAR, CLCF1, CSF1, CSF2, CXCL1, CXCL10, CXCL11, CXCL2, CXCL3, CXCL6, DENND5A, DNAJB4, DRAM1, DUSP1, DUSP2, DUSP4, DUSP5, EDN1, EFNA1, EGR1, EGR2, EGR3, EHD1, EIF1, ETS2, F2RL1, F3, FJX1, FOS, FOSB, FOSL1, FOSL2, FUT4, G0S2, GADD45A, GADD45B, GCH1, GEM, GFPT2, GPR183, HBEGF, HES1, ICAM1, ICOSLG, ID2, IER2, IER3, IER5, IFIH1, IFIT2, IFNGR2, IL12B, IL15RA, IL18, IL1A, IL1B, IL23A, IL6, IL6ST, IL7R, INHBA, IRF1, IRS2, JAG1, JUN, JUNB, KDM6B, KLF10, KLF2, KLF4, KLF6, KLF9, KYNLU, LAMB3, LDLR, LIF, LITAF, MAFF, MAP2K3, MAP3K8, MARCKS, MCL1, MSC, MXD1, MYC, NAMPT, NFAT5, NFE2L2, NFIL3, NFKB1, NFKB2, NFKBIA, NFKBIE, NINJ1, NR4A1, NR4A2, NR4A3, OLR1, PANX1, PDE4B, PDLM5, PER1, PFKFB3, PHLDA1, PHLDA2, PLAU, PLAUR, PLEK, PLK2, PLPP3, PMEPA1, PNRC1, PPP1R15A, PTGER4, PTGS2, PTPRE, PTX3, RCAN1, REL, RELA, RELB, RHOB, RIGI, RIPK2, RNF19B, SAT1, SDC4, SERPINB2, SERPINB8, SERPINE1, SGK1, SIK1, SLC16A6, SLC2A3, SLC2A6, SMAD3, SNN, SOCS3, SOD2, SPHK1, SPSB1, SQSTM1, STAT5A, TANK, TAP1, TGIF1, TIPARP, TLR2, TNC, TNF, TNFAIP2, TNFAIP3, TNFAIP6, TNFAIP8, TNFRSF9, TNFSF9, TNIP1, TNIP2, TRAF1, TRIB1, TRIP10, TSC2D1, TUBB2A, VEGFA, YRDC, ZBTB10, ZC3H12A, ZFP36
HALLMARK_IL6_JAK_STAT3_SIGNALING	A2M, ACVR1B, ACVRL1, BAK1, CBL, CCL7, CCR1, CD14, CD36, CD38, CD44, CD9, CNTFR, CRLF2, CSF1, CSF2, CSF2RA, CSF2RB, CSF3R, CXCL1, CXCL10, CXCL11, CXCL13, CXCL3, CXCL9, DNTT, EBI3, FAS, GRB2, HAX1, HMOX1, IFNAR1, IFNGR1, IFNGR2, IL10RB, IL12RB1, IL13RA1, IL15RA, IL17RA, IL17RB, IL18R1, IL1B, IL1R1, IL1R2, IL2RA, IL2RG, IL3RA, IL4R, IL6, IL6ST, IL7, IL9R, INHBE, IRF1, IRF9, ITGA4, ITGB3, JUN, LEPR, LTB, LTBR, MAP3K8, MYD88, OSMR, PDGFC, PF4, PIK3R5, PIM1, PLA2G2A, PTPN1, PTPN11, PTPN2, REG1A, SOCS1, SOCS3, STAM2, STAT1, STAT2, STAT3, TGFB1, TLR2, TNF, TNFRSF12A, TNFRSF1A, TNFRSF1B, TNFRSF21, TYK2
HALLMARK_IL2_STATS_SIGNALING	ABC1, ADAM19, AGER, AHCA, AHNAK, AHR, ALCAM, AMACR, ANXA4, APLP1, ARL4A, BATF, BATF3, BCL2, BCL2L1, BHLHE40, BMP2, BMPR2, CA2, CAPG, CAPN3, CASP3, CCND2, CCND3, CCNE1, CCR4, CD44, CD48, CD79B, CD81, CD83, CD86, CDC4SE2, CDC6, CDCP1, CDKN1C, CISH, CKAP4, COCH, COL6A1, CSF1, CSF2, CST7, CTLA4, CTSZ, CXCL10, CYFIP1, DCPS, DENND5A, DHRS3, DRC1, ECM1, EEF1AKMT1, EMP1, ENO3, ENPP1, EOMES, ETFBKMT, ETV4, F2RL2, FAH, FGL2, FLT3LG, FURIN, GABARAPL1, GADD45B, GALM, GATA1, GBP4, GLIPR2, GPR65, GPR83, GPX4, GSTO1, GUCY1B1, HIPK2, HK2, HOPX, HUWE1, HYCC2, ICOS, IFITM3, IFNGR1, IGF1R, IGF2R, IKZF2, IKZF4, IL10, IL10RA, IL13, IL18R1, IL1R2, IL1R1, IL2RA, IL2RB, IL3RA, IL4R, IRF4, IRF6, IRF8, ITGA6, ITGAE, ITGAV, ITIH5, KLF6, LCLAT1, LIF, LRIG1, LRRC8C, LTB, MAFF, MAP3K8, MAP6, MAPKAPK2, MUC1, MXD1, MYC, MYO1C, MYO1E, NCOA3, NCS1, NDRG1, NFIL3, NFKBIZ, NOP2, NRP1, NT5E, ODC1, P2RX4, P4HA1, PDCD2L, PENK, PHLDA1, PHTF2, PIM1, PLAGL1, PLEC, PLIN2, PLPP1, PLSCR1, PNP, POU2F1, PRAF2, PRKCH, PRNP, PTCH1, PTGER2, PTH1R, PTRH2, PUS1, RABGAP1L, RGS16, RHOB, RHOH, RNH1, RORA, RRAGD, S100A1, SCN9A, SELL, SELP, SERPINB6, SERPINC1, SH3BGR2, SHE, SLC1A5, SLC2A2, SLC2A3, SLC39A8, SMPDL3A, SNX14, SNX9, SOCS1, SOCS2, SPPI1, SPRED2, SPRY4, ST3GAL4, SWAP70, SYNGR2, SYT11, TGM2, TIAM1, TLR7, TNFRSF18, TNFRSF1B, TNFRSF21, TNFRSF4, TNFRSF8, TNFRSF9, TNFSF10, TNFSF11, TRAF1, TTC39B, TWSG1, UCK2, UMPS, WLS, XBP1
HALLMARK_INTERFERON_GAMMA_RESPONSE	ADAR, APOL6, ARID5B, ARL4A, AUTS2, B2M, BANK1, BATF2, BPGM, BST2, BTG1, C1R, C1S, CASP1, CASP3, CASP4, CASP7, CASP8, CCL2, CCL5, CCL7, CD274, CD38, CD40, CD69, CD74, CD86, CDKN1A, CFB, CFH, CIITA, CMKLR1, CMKP2, CMTR1, CSF2RB, CXCL10, CXCL11, CXCL9, DDX60, DHX58, EIF2AK2, EIF4E3, EPSTI1, FAS, FCGR1A, FGL2, FPR1, GBP4, GBP6, GCH1, GPR18, GZMA, HELZ2, HERC6, HIF1A, HLA-A, HLA-B, HLA-DMA, HLA-DQA1, HLA-DRB1, HLA-G, ICAM1, IDO1, IFI27, IFI30, IFI35, IFI44L, IFI44L, IFI44L, IFI44L, IFIT1, IFIT2, IFIT3, IFITM2, IFITM3, IFNAR2, IL10RA, IL15, IL15RA, IL18BP, IL2RB, IL4R, IL6, IL7, IRF1, IRF2, IRF4, IRF5, IRF7, IRF8, IRF9, ISG15, ISG20, ISOC1, ITGB7, JAK2, KLRK1, LAP3, LAT52, LCP2, LGALS3BP, LY6E, LYSMD2, MARCHF1, METTL7B, MT2A, MTHFD2, MVP, MX1, MX2, MYD88, NAMPT, NCOA3, NFKB1, NFKBIA, NLRC5, NMI, NOD1, NUP93, OAS2, OAS3, OASL, OGFR, P2RY14, PARP12, PARP14, PDE4B, PELI1, PFKP, PIM1, PLA2G4A, PLSCR1, PML, PNP, PNPT1, PSMA2, PSMA3, PSMB10, PSMB2, PSMB8, PSMB9, PSME1, PSME2, PTGS2, PTPN1, PTPN2, PTPN6, RAPGEF6, RBCK1, RIG1, RIPK1, RIPK2, RNF213, RNF31, RSAD2, RTP4, SAMD9L, SAMHD1, SECTM1, SELP, SERPING1, SLAMF7, SLC25A28, SOCS1, SOCS3, SOD2, SP110, SPPL2A, SRI, SSPN, ST3GAL5, ST8SIA4, STAT1, STAT2, STAT3, STAT4, TAP1, TAPBP, TDRD7, TNFAIP2, TNFAIP3, TNFAIP6, TNFSF10, TOR1B, TRAFD1, TRIM14, TRIM21, TRIM25, TRIM26, TXNIP, UBE2L6, UPP1, USP18, VAMP5, VAMP8, VCAM1, WARS1, XAF1, XCL1, ZBP1, ZNFX1
HALLMARK_PI3K_AKT_MTOR_SIGNALING	ACACA, ACTR2, ACTR3, ADCY2, AKT1, AKT1S1, AP2M1, ARF1, ARHGDIA, ARPC3, ATF1, CAB39, CAB39L, CALR, CAMK4, CDK1, CDK2, CDK4, CDKN1A, CDKN1B, CFL1, CLTC, CSNK2B, CXCR4, DAPP1, DDIT3, DUSP3, E2F1, ECSIT, EGFR, EIF4E, FASLG, FGF17, FGF22, FGF6, GNA14, GNGT1, GRB2, GRK2, GSK3B, HRAS, HSP90B1, IL2RG, IL4, IRAK4, ITPR2, LCK, MAP2K3, MAP2K6, MAP3K7, MAPK1, MAPK10, MAPK8, MAPK9, MAPKAP1, MKNK1, MKNK2, MYD88, NCK1, NFKBIB, NGF, NOD1, PAK4, PDK1, PFN1, PIK3R3, PIKFYVE, PIN1, PITX2, PLA2G12A, PLCB1, PLCG1, PPP1CA, PPP2R1B, PRKAA2, PRKAG1, PRKAR2A, PRKCB, PTEN, PTPN11, RAC1, RAF1, RALB, RIPK1, RIT1, RPS6KA1, RPS6KA3, RPTOR, SFN, SLA, SLC2A1,

GENE SET	GENE SYMBOLS
	SMAD2, SQSTM1, STAT2, TBK1, THEM4, TIAM1, TNFRSF1A, TRAF2, TRIB3, TSC2, UBE2D3, UBE2N, VAV3, YWHA _B
HALLMARK_OXIDATIVE_PHOSPHORYLATION	ABCB7, ACAA1, ACAA2, ACADM, ACADSB, ACADVL, ACAT1, ACO2, AFG3L2, AIFM1, ALAS1, ALDH6A1, ATP1B1, ATP5F1A, ATP5F1B, ATP5F1C, ATP5F1D, ATP5F1E, ATP5MC1, ATP5MC2, ATP5MC3, ATP5ME, ATP5MF, ATP5MG, ATP5PB, ATP5PD, ATP5PF, ATP5PO, ATP6AP1, ATP6V0B, ATP6V0C, ATP6V0E1, ATP6V1C1, ATP6V1D, ATP6V1E1, ATP6V1F, ATP6V1G1, ATP6V1H, BAX, BCKDHA, BDH2, CASP7, COX10, COX11, COX15, COX17, COX4I1, COX5A, COX5B, COX6A1, COX6B1, COX6C, COX7A2, COX7A2L, COX7B, COX7C, COX8A, CPT1A, CS, CYB5A, CYB5R3, CYC1, CYCS, DCR1, DLAT, DLD, DLST, ECH1, ECHS1, ECI1, ETFA, ETFB, ETFDH, FDX1, FH, FXN, GLUD1, GOT2, GPI, GPX4, GRPEL1, HADHA, HADHB, HCCS, HSD17B10, HSPA9, HTRA2, IDH1, IDH2, IDH3A, IDH3B, IDH3G, IMMT, ISCA1, ISCU, LDHA, LDHB, LRPPRC, MAOB, MDH1, MDH2, MFN2, MGST3, MPC1, MRPL11, MRPL15, MRPL34, MRPL35, MRPS11, MRPS12, MRPS15, MRPS22, MRPS30, MTRF1, MTRR, MTX2, NDUFA1, NDUFA2, NDUFA3, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NNT, NQO2, OAT, OGDH, OPA1, OXA1L, PDHA1, PDHB, PDHX, PDK4, PDP1, PHB2, PHYH, PMPCA, POLR2F, POR, PRDX3, RETSAT, RHOT1, RHOT2, SDHA, SDHB, SDHC, SDHD, SLC25A11, SLC25A12, SLC25A20, SLC25A3, SLC25A4, SLC25A5, SLC25A6, SUCLA2, SUCLG1, SUPV3L1, SURF1, TCIRG1, TIMM10, TIMM13, TIMM17A, TIMM50, TIMM8B, TIMM9, TOMM22, TOMM70, UQCRC10, UQCRC11, UQCRCB, UQCRC1, UQCRC2, UQCRCFS1, UQCRRH, UQCRRQ, VDAC1, VDAC2, VDAC3
HALLMARK_GLYCOLYSIS	ABCB6, ADORA2B, AGL, AGRN, AK3, AK4, AKR1A1, ALDH7A1, ALDH9A1, ALDOA, ALDOB, ALG1, ANG, ANGPTL4, ANKZF1, ARPP19, ARTN, AURKA, B3GALT6, B3GAT1, B3GAT3, B3GNT3, B4GALT1, B4GALT2, B4GALT4, B4GALT7, BIK, BPNT1, CACNA1H, CAPN5, CASP6, CD44, CDK1, CENPA, CHPF, CHPF2, CHST1, CHST12, CHST2, CHST4, CHST6, CITED2, CLDN3, CLDN9, CLN6, COG2, COL5A1, COPB2, CTH, CXCR4, CYB5A, DCN, DDIR4, DEPDC1, DLD, DPYSL4, DSC2, ECD, EFNA3, EGFR, EGLN3, ELF3, ENO1, ENO2, ERO1A, EXT1, EXT2, FAM162A, FBP2, FKBP4, FUT8, G6PD, GAL3ST1, GALE, GALK1, GALK2, GAPDHS, GCLC, GFPT1, GFUS, GLCE, GLRX, GMPPA, GMPPB, GNE, GNPDAA1, GOT1, GOT2, GPC1, GPC3, GPC4, GPR87, GUSB, GYS1, GYS2, HAX1, HDLBP, HK2, HMMR, HOMER1, HS2ST1, HS6ST2, HSPA5, IDH1, IDUA, IER3, IGFBP3, IL13RA1, IRS2, ISG20, KDELR3, KIF20A, KIF2A, LCT, LDHA, LDHC, LHPP, LHX9, MDH1, MDH2, ME1, ME2, MED24, MERTK, MET, MIF, MIOX, MPI, MX11, NANP, NASP, NDST3, NDUFV3, NOL3, NSDHL, NT5E, P4HA1, P4HA2, PAM, PAXIP1, PC, PDK3, PFKFB1, PFKP, PGAM1, PGAM2, PGK1, PGLS, PGM2, PHKA2, PKM, PKP2, PLOD1, PLOD2, PMM2, POLR3K, PPFFIA4, PPIA, PPP2CB, PRPS1, PSMC4, PYGB, PYGL, QSOX1, RARS1, RBCK1, RPE, RRAGD, SAP30, SDC1, SDC2, SDC3, SDHC, SLC16A3, SLC25A10, SLC25A13, SLC35A3, SLC37A4, SOD1, SOX9, SPAG4, SRD5A3, STC1, STC2, STMN1, TALDO1, TFF3, TGFA, TGFBI, TKTL1, TPBG, TPI1, TPST1, TXN, UGP2, VCAN, VEGFA, VLDR, XYLT2, ZNF292
SRS_EXTENDED_GENE_SET	SLC25A38, DNAJA3, NAT10, THOC1, MRPS9, PGS1, UBAP1, USP5, TTC3, SH3GLB1, BMS1, FBXO31, ARL14EP, CCNB1IP1, DYRK2, ADGRE3, MDC1, TDRD9, ZAP70